Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COSENSE-1: A Feasibility Study for Using a Functional Precision Medicine Platform to Select Oxaliplatin-based Versus Irinotecan-based Chemotherapy Regimens for Patients With Metastatic Colorectal Cancer

NCT06907342 is registered in ClinicalTrials.gov with St. Olavs Hospital as lead sponsor.

NCT NCT06907342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COSENSE-1: A Feasibility Study for Using a Functional Precision Medicine Platform to Select Oxaliplatin-based Versus Irinotecan-based Chemotherapy Regimens for Patients With Metastatic Colorectal Cancer
Lead sponsor
St. Olavs Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 23, 2025
Completion date
September 30, 2040
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

core needle biopsy, first-line treatment, metastatic colorectal cancer, organoids, tumor, colorectal, tumoroid